Lung Cancer: Page 4

Nucleix advances EpiCheck lung cancer platform

By LabPulse.com staff writers

Nucleix completed a side-by-side analysis that compared EpiCheck against conventional bisulfite approaches in patients with stage I lung cancer. EpiCheck revealed "many promising markers" that could indicate early-stage lung disease; meanwhile, the bisulfite approach only identified 1% of what EpiCheck detected.

January 5, 2022

Study recommends screening for adults at risk of multiple myeloma

By Leah Sherwood

"We know that in cancers such as breast cancer and lung cancer screening, early detection and early intervention can make a difference in patient survival," senior author Dr. Irene Ghobrial of the Dana-Farber Cancer Institute in Boston said in a statement. "We have shown for the first time that with highly sensitive screening techniques, it may eventually be possible to make a difference in the survival of people at elevated risk for multiple myeloma."

December 10, 2021

Quest offers Biocept's liquid biopsy test

By LabPulse.com staff writers

Biocept's Target Selector NGS Lung Panel helps with the genomic profiling of patients with advanced non-small cell lung cancer. The test helps physicians identify a potential treatment target and monitor the effectiveness of patients' treatments, according to Quest.

December 1, 2021

Cancer mortality declined by 27% over past five decades

By LabPulse.com staff writers

Mortality rates decreased "significantly" for 12 of the 15 top cancer sites analyzed, according to a team led by Tyler Kratzer from the American Cancer Society. The researchers also found greater mortality declines for certain cancers in particular years, such as lung cancer being 44% lower in 2019 compared with its peak rate in 1993.

November 11, 2021

Lab Genomics, Canexia secure MolDX coverage for DNA assay

By LabPulse.com staff writers

The decision allows for Medicare coverage of Follow It for breast, lung, and colorectal cancers, the two firms said. Follow It can help guide cancer treatment, according to the companies.

November 1, 2021

Immunis.AI closes on funding for immunogenomic platform

By LabPulse.com staff writers

The company said the funding will support further validation and commercialization of the company's prostate cancer molecular test and will expand development of new tests in breast, colon, lung cancer, and other cancers.

September 30, 2021

Thermo Fisher gets FDA approval for lung cancer test

By LabPulse.com staff writers

The test will be used as a companion diagnostic to identify patients who are candidates for treatment with Exkivity (mobocertinib) from Takeda Pharmaceutical. The Oncomine Dx Target Test is intended to help identify patients who have epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

September 16, 2021

Researchers tout success of AI blood testing tech

By LabPulse.com staff writers

Called DNA evaluation of fragments for early interception (DELFI), the test detected 94% of lung cancers in samples from nearly 800 individuals with and without cancer, according to the center.

August 19, 2021

Liquid biopsy may detect ALK fusions in lung cancer patients

By LabPulse.com staff writers

Liquid biopsy also could be used to serially monitor the development of mechanisms of resistance in response to targeted therapy.

July 27, 2021

Oncologists urge faster biomarker results for lung cancer patients

By Emily Hayes

Out of 170 clinicians polled, the vast majority (98%) said that they felt it was important to get biomarker test results back in from one to two weeks, but while 63% reported that they get results in this time frame, 37% said that from three to four weeks was the average.

June 8, 2021

FDA expands use of Qiagen lung cancer mutation test

By LabPulse.com staff writers

Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in non-small cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.

June 1, 2021

EarlySign touts study of AI for nonsmall cell lung cancer

By LabPulse.com staff writers

Based on clinical characteristics and laboratory testing performed nine to 12 months before a clinical diagnosis of cancer, the EarlySign model identified lung cancer with a sensitivity of 40.3% and specificity of 95%, according to the company. A positive test result indicated a thirteenfold elevation in the odds of lung cancer.

May 26, 2021

Previous Page

Page 4 of 7

Next Page